Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVolex Regulatory News (VLX)

Share Price Information for Volex (VLX)

Share Price is delayed by 15 minutes
Get Live Data
649.00    -30.00 (-4.42%)
Bid:
648.00
Ask:
650.00
Spread: 2.00 (0.309%)
Market Cap: £1.19b
VLX Live PriceLast checked at - London Stock Exchange

Intraday Volex Share Chart

Trading Update

15 Apr 2021 07:00

RNS Number : 5159V
Volex PLC
15 April 2021
 

15 April 2021

 

Volex plc

 

Trading update

 

Volex plc (AIM:VLX), the global supplier of integrated manufacturing services and power products, is pleased to provide the following update on trading ahead of the scheduled announcement of the Group's full year results for the 52 weeks ended 4 April 20211 on 17 June 2021. 

 

Financial and operational performance

The Group delivered a robust performance in the second half of the financial year, underpinned by strong demand from customers in the consumer electronics and electric vehicle markets.

 

The performance for the period includes over $52 million of revenue from electric vehicle customers, a significant increase of 187% compared to the previous year, as we expanded our customer base and product offering in this market.

 

There has also been an overall stabilisation in demand from our core medical and industrial markets as well as healthy year-on-year growth from data centre customers as the trend towards home-working continues.

 

As a result, revenue for the full year will be ahead of market expectations and be at least $440 million while underlying operating profit is expected to be at least $41 million, ahead of the most recently guided range.

 

Margins benefited from foreign exchange movements and favourable commodity pricing in the first half of the financial year and, although these unwound in the second half as anticipated, the Group delivered strong year-on-year margin growth. The underlying operating margin achieved for the full year represents a satisfactory balance between revenue growth and profitability. 

Although the business and operational challenges posed by Covid-19 have not abated, all sites have remained fully operational even as our local teams have prioritised keeping our employees safe.

 

Acquisition activity and balance sheet

The acquisition of De-Ka Elektroteknik Sanayi ve Ticaret Anonim Şirketi ("DE-KA") completed on 18 February 2021 and its integration into the wider Volex business is progressing as planned, accelerating our strategy of creating the most efficient and lowest cost global producer in the industry.

 

DE-KA's sales and profits are currently significantly ahead of the previous year and the business continues to enjoy very strong demand in its core, white goods markets.

 

Following the acquisition of DE-KA, Group net debt (excluding lease liabilities) will be approximately $6 million. Having completed a successful refinancing in November 2020, Volex retains a high degree of financial flexibility and management continues to advance targeted investment opportunities, whilst maintaining its highly disciplined approach to potential acquisitions.

 

The Group expects to announce a recommended dividend for FY2021 that is no less than 2.2 pence per share.

 

Executive Chairman, Nat Rothschild commented:

"Volex delivered a particularly strong end to the period with our resilient business model meeting the challenges posed by the Covid-19 pandemic head-on. Robust demand in the electric vehicle and consumer electronics markets underpinned our performance in the second half and, thanks to our diverse customer base and global footprint, we are well placed to deliver on the next stage of our development as we look to increase investment and grow our business. Whilst we are now entering a more challenging inflationary environment, we aim to defend the significant margin gains we have made. Unless future lockdown measures severely disrupt our customers or operations, we are confident of further revenue and profit progression in FY2022."

 

This announcement, released by Volex plc, contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

 

For further information please contact: 

 

Volex plc +44 (0) 7747 488 785

Nat Rothschild, Executive Chairman

Jon Boaden, Chief Financial Officer

 

Powerscourt - Media Enquiries +44 (0)20 7250 1446

James White

Jack Holden

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Shaun Dobson

Iqra Amin

 

HSBC Bank Plc - Joint Broker +44 (0)20 7991 8888

Simon Alexander

Joe Weaving

 

Notes:

1. All figures in this trading update are unaudited. Audited amounts will be included in our full year results announcement on 17 June 2021.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFFISFISLIL
Date   Source Headline
5th Aug 202010:28 amRNSPDMR / PCA Dealing
30th Jul 20204:29 pmRNSCompany Secretary Change
30th Jul 20204:26 pmRNSResult of AGM
30th Jul 20207:00 amRNSAGM Statement
6th Jul 20203:41 pmRNSDirector/PDMR Shareholding
3rd Jul 20207:00 amRNSNotice of AGM and Annual Report and Accounts
26th Jun 20203:50 pmRNSHolding(s) in Company
26th Jun 20207:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
23rd Jun 20207:00 amRNSDirector/PDMR Shareholding
22nd Jun 20206:23 pmRNSDirector/PDMR Shareholding
18th Jun 20207:01 amRNSInvestor Presentation
18th Jun 20207:00 amRNSPreliminary Group Results FY2020
1st Jun 20204:41 pmRNSSecond Price Monitoring Extn
1st Jun 20204:36 pmRNSPrice Monitoring Extension
29th Apr 20204:19 pmRNSDirector/PDMR Shareholding
24th Apr 20204:36 pmRNSPrice Monitoring Extension
20th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20207:00 amRNSTrading Update
6th Apr 20204:35 pmRNSPrice Monitoring Extension
6th Apr 20201:31 pmRNSDirector/PDMR Shareholding
3rd Apr 20203:41 pmRNSDirector/PDMR Shareholding
1st Apr 20202:54 pmRNSDirector/PDMR Shareholding
30th Mar 20201:42 pmRNSDirector/PDMR Shareholding
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSChange of Registered Office
23rd Mar 20204:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20205:00 pmRNSDirector/PDMR Shareholding
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
11th Mar 20202:03 pmRNSHolding(s) in Company
9th Mar 20204:30 pmRNSDirector/PDMR Shareholding
6th Mar 20204:41 pmRNSSecond Price Monitoring Extn
6th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:07 pmRNSSecond Price Monitoring Extn
6th Mar 202012:02 pmRNSPrice Monitoring Extension
2nd Mar 202012:47 pmRNSDeferred Consideration for Servatron Acquisition
26th Feb 20203:49 pmRNSEBT Share Purchase
17th Feb 20207:00 amRNSStatement Regarding Situation in China - Update
13th Feb 20205:26 pmRNSEBT Share Purchase
10th Feb 20209:57 amRNSStatement Regarding Current Situation in China
15th Jan 20203:47 pmRNSHolding(s) in Company
15th Jan 20203:34 pmRNSDirector/PDMR Shareholding
6th Jan 20201:19 pmRNSHolding(s) in Company
6th Jan 20201:17 pmRNSHolding(s) in Company
20th Dec 20196:10 pmRNSHolding(s) in Company
19th Dec 20193:41 pmRNSDirector/PDMR Shareholding
18th Dec 20193:37 pmRNSHolding(s) in Company
11th Dec 20199:42 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.